Regeneron Pharmaceuticals, Inc. (REGN) Company Profile & Statistics

Regeneron Pharmaceuticals, Inc.
REGN
(Nasdaq - US)
Closed
895.82
+1.83 (+0.20%)
in:usd•As of: Apr 19, 2024 15:59 UTC -4
Open
917.96
High
920.00
Low
891.08

About Regeneron Pharmaceuticals, Inc.

CEO

Leonard S. Schleifer

Headquarters

777 old saw mill river road

tarrytown, ny 10591, united states

Auditor

PricewaterhouseCoopers LLP

Employees

13,450

Share Holders

167

Website

www.regeneron.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Regeneron Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization ²	98.33B
Enterprise Value	98.30B
Enterprise Value/EBITDA (ttm)	22.00
Price to Earnings Ratio (ttm)	23.98
Price to Book (mrq)	3.81
Price to Sales (ttm)	7.54
Price to Cash (ytd)	20.83

Profitability

Gross Margin (ttm)	86.17%
Operating Margin (ttm)	33.03%
Profit Margin (ttm)	30.07%
Return on Equity (ttm)	17.61%
Return on Invested Capital (ttm)	14.44%
Return on Assets (ttm)	13.76%

Income Statement

Revenue (ttm)	13.12B
Revenue Per Share (ttm)	119.51
Gross Profit (ttm)	11.30B
EBITDA (ttm)³	4.47B
Net Income Avi to Common (ttm)	3.95B
Diluted EPS (ttm)	34.75

Share Statistics

Beta (5Y Monthly)	0.11
52-Week Change	10.75%
S&P500 52-Week Change	19.56%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	109.76M
Dividend Yield	0.00%
Float ⁴	100.07M
% Held by Insiders	8.83%
% Held by Institutions	83.31%

Balance Sheet

Total Cash (mrq)	10.84B
Total Cash Per Share (mrq)	98.80
Total Debt (mrq)	2.70B
Total Debt/Equity (mrq)	10.41%
Current Ratio (mrq)	5.69%
Quick Ratio (mrq)	4.94%
Book Value Per Share (mrq)	237.41

Cash Flow

Operating Cash Flow Per Share (ytd)	40.40
Free Cash Flow (ytd)	3.88B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Regeneron Pharmaceuticals, Inc.

Trade With A Regulated Broker